沙利度胺因可导致胎儿畸形而一度退出市场。近年国外研究报道,利用沙利度胺的抗血管生成、免疫调节以及促进骨髓瘤细胞凋亡作用可用于多发性骨髓瘤的治疗。经临床研究证实,使用沙利度胺治疗可使多发性骨髓瘤患者的病情得到缓解并延长生存期。 Thalidomide may have withdrawn from the market as a result of fetal malformations. In recent years, foreign studies have reported that the use of thalidomide anti-angiogenesis, immune regulation and promote apoptosis of myeloma cells can be used for the treatment of multiple myeloma. Clinical studies have confirmed that the use of thalidomide can alleviate the condition of patients with multiple myeloma and prolong survival.